{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:20:06Z","timestamp":1790158806046,"version":"4.1.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1016\/j.hoc.2004.06.019","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T10:53:30Z","timestamp":1113821610000},"page":"1355-1377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias"],"prefix":"10.1016","volume":"18","author":[{"given":"Janet L.","family":"Kwiatkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.hoc.2004.06.019_bib1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0002-9343(78)90772-6","article-title":"The natural history of stroke in sickle cell disease","volume":"65","author":"Powars","year":"1978","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.hoc.2004.06.019_bib2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0022-3476(95)70204-0","article-title":"Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions","volume":"126","author":"Pegelow","year":"1995","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM199807023390102","article-title":"Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography","volume":"339","author":"Adams","year":"1998","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2004.06.019_bib4","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1182\/blood.V99.8.3014","article-title":"Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease","volume":"99","author":"Pegelow","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2004.06.019_bib5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/088307380001500510","article-title":"Multicenter prospective study of children with sickle cell disease: radiographic and psychometric correlation","volume":"15","author":"Bernaudin","year":"2000","journal-title":"J Child Neurol"},{"issue":"6 pt 1","key":"10.1016\/j.hoc.2004.06.019_bib6","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1542\/peds.97.6.864","article-title":"Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease","volume":"97","author":"Armstrong","year":"1996","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.hoc.2004.06.019_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1067\/mpd.2001.117580","article-title":"Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease","volume":"139","author":"Miller","year":"2001","journal-title":"J Pediatr"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2004.06.019_bib8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0037-1963(01)90054-X","article-title":"Consensus document for transfusion-related iron overload","volume":"38","author":"Vichinsky","year":"2001","journal-title":"Sem Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2004.06.019_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0037-1963(01)90058-7","article-title":"Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease","volume":"38","author":"Ballas","year":"2001","journal-title":"Sem Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2004.06.019_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0955-3886(00)00087-4","article-title":"The importance of non-transferrin bound iron in disorders of iron metabolism","volume":"23","author":"Breuer","year":"2000","journal-title":"Transfus Sci"},{"issue":"8653","key":"10.1016\/j.hoc.2004.06.019_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(89)90264-X","article-title":"Survival and causes of death in thalassaemia major","volume":"2","author":"Zurlo","year":"1989","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/adc.59.1.67","article-title":"Cirrhosis associated with multiple transfusions in thalassaemia","volume":"59","author":"Jean","year":"1984","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7326\/0003-4819-80-1-65","article-title":"Carbohydrate homoeostasis and pancreatic islet cell function in thalassemia","volume":"80","author":"Lassman","year":"1974","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0022-3476(85)80488-1","article-title":"Growth and sexual maturation in thalassemia major","volume":"106","author":"Borgna-Pignatti","year":"1985","journal-title":"J Pediatr"},{"key":"10.1016\/j.hoc.2004.06.019_bib15","unstructured":"Harmatz P, Butensky E, Fung E, Louie L, Theil E, Ferrell L. Organ injury in chronically transfused patients with beta thalassemia or sickle cell disease. Presented at the 30th Anniversary Meeting of the National Sickle Cell Disease Program. Washington DC: September 17\u201321, 2002."},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood.V96.1.76","article-title":"Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy","volume":"96","author":"Harmatz","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2004.06.019_bib17","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood-2003-06-1919","article-title":"Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease","volume":"103","author":"Wood","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2004.06.019_bib18","unstructured":"Fung EB, Harmatz PR, Madden J, Vichinsky E. Group M-CSoIOS: organ dysfunction in iron overloaded patients with beta-thalassemia or sickle cell disease. Presented at the 27th Annual Meeting of the National Sickle Cell Disease Program. Los Angeles: April 18\u201321, 2004."},{"issue":"4","key":"10.1016\/j.hoc.2004.06.019_bib19","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1046\/j.1365-2141.2000.02298.x","article-title":"Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major","volume":"110","author":"Telfer","year":"2000","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ajh.2830420116","article-title":"Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major","volume":"42","author":"Brittenham","year":"1993","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.hoc.2004.06.019_bib21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199409013310903","article-title":"Survival in medically treated patients with homozygous beta thalassemia","volume":"331","author":"Olivieri","year":"1994","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2004.06.019_bib22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/jcp.39.3.253","article-title":"Serum ferritin concentration in sickle crisis","volume":"39","author":"Brownell","year":"1986","journal-title":"J Clin Pathol"},{"issue":"4","key":"10.1016\/j.hoc.2004.06.019_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/adc.53.4.319","article-title":"Value of serum ferritin estimation in sickle cell anaemia","volume":"53","author":"Hussain","year":"1978","journal-title":"Arch Dis Child"},{"issue":"4","key":"10.1016\/j.hoc.2004.06.019_bib24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00043426-200205000-00013","article-title":"Longitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP)","volume":"24","author":"Files","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7690","key":"10.1016\/j.hoc.2004.06.019_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0140-6736(71)90838-5","article-title":"Measurement of liver-iron concentration in needle-biopsy specimens","volume":"1","author":"Barry","year":"1971","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.hoc.2004.06.019_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJM200008033430503","article-title":"Hepatic iron concentration and total body iron stores in thalassemia major","volume":"343","author":"Angelucci","year":"2000","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2004.06.019_bib27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0168-8278(96)80070-5","article-title":"Variability in hepatic iron concentration measurement from needle-biopsy specimens","volume":"25","author":"Villeneuve","year":"1996","journal-title":"J Hepatol"},{"issue":"23","key":"10.1016\/j.hoc.2004.06.019_bib28","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1053\/euhj.2001.2822","article-title":"Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload","volume":"22","author":"Anderson","year":"2001","journal-title":"Eur Heart J"},{"issue":"27","key":"10.1016\/j.hoc.2004.06.019_bib29","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJM198212303072703","article-title":"Magnetic-susceptibility measurement of human iron stores","volume":"307","author":"Brittenham","year":"1982","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2004.06.019_bib30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/jmri.10080","article-title":"Evaluation of iron overload by single voxel MRS measurement of liver T2","volume":"15","author":"Wang","year":"2002","journal-title":"J Mag Reson Imag"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/jmri.10332","article-title":"A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload","volume":"18","author":"Westwood","year":"2003","journal-title":"J Magn Reson Imag"},{"issue":"6","key":"10.1016\/j.hoc.2004.06.019_bib32","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2214\/ajr.175.6.1751567","article-title":"T2 relaxation rate as an index of pituitary iron overload in patients with beta-thalassemia major","volume":"175","author":"Argyropoulou","year":"2000","journal-title":"AJR"},{"issue":"3","key":"10.1016\/j.hoc.2004.06.019_bib33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2141.2003.04772.x","article-title":"Magnetic resonance screening of iron status in transfusion-dependent beta-thalassaemia patients","volume":"124","author":"Ooi","year":"2004","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2002-06-1723","article-title":"Noninvasive measurement of iron: report of an NIDDK workshop","volume":"101","author":"Brittenham","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2004.06.019_bib35","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0090-9556(25)07467-7","article-title":"Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients","volume":"21","author":"Lee","year":"1993","journal-title":"Drug Metab Disp"},{"issue":"8075","key":"10.1016\/j.hoc.2004.06.019_bib36","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(78)90968-6","article-title":"Prevention of iron loading in transfusion-dependent thalassaemia","volume":"1","author":"Pippard","year":"1978","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.hoc.2004.06.019_bib37","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1056\/NEJM198101153040311","article-title":"Vitamin C and iron","volume":"304","author":"Nienhuis","year":"1981","journal-title":"N Engl J Med"},{"issue":"909","key":"10.1016\/j.hoc.2004.06.019_bib38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/bmj.2.5909.16","article-title":"Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress","volume":"2","author":"Barry","year":"1974","journal-title":"BMJ"},{"key":"10.1016\/j.hoc.2004.06.019_bib39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2141.1984.tb06096.x","article-title":"Depletion of excessive liver iron stores with desferrioxamine","volume":"58","author":"Cohen","year":"1984","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1016\/j.hoc.2004.06.019_bib40","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM198506203122503","article-title":"Prevention of cardiac disease by sucutaneous deferoxamine in patients with thalassemia major","volume":"312","author":"Wolfe","year":"1985","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2004.06.019_bib41","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1378\/chest.103.4.1276","article-title":"Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major","volume":"103","author":"Wacker","year":"1993","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.hoc.2004.06.019_bib42","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.V95.4.1229.004k32_1229_1236","article-title":"Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia","volume":"95","author":"Davis","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2004.06.019_bib43","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/01.CIR.30.5.698","article-title":"Late cardiac complications of chronic, severe refractory anemia and hemochromatosis","volume":"30","author":"Engle","year":"1964","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.hoc.2004.06.019_bib44","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM199409013310902","article-title":"Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major","volume":"331","author":"Brittenham","year":"1994","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2004.06.019_bib45","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0022-3476(78)80317-5","article-title":"Excretion of iron in response to deferoxamine in sickle cell anemia","volume":"92","author":"Cohen","year":"1978","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajh.2830070109","article-title":"Iron chelation therapy in sickle cell anemia","volume":"7","author":"Cohen","year":"1979","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.hoc.2004.06.019_bib47","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJM198604033141402","article-title":"Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions","volume":"314","author":"Olivieri","year":"1986","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2004.06.019_bib48","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1136\/bjo.68.12.873","article-title":"Ocular changes in patients undergoing long term desferrioxamine treatment","volume":"68","author":"Arden","year":"1984","journal-title":"Br J Ophthal"},{"issue":"3","key":"10.1016\/j.hoc.2004.06.019_bib49","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2141.1989.tb07761.x","article-title":"Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage","volume":"73","author":"Porter","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2004.06.019_bib50","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01955263","article-title":"Growth and development in thalassamia major patients with severe bone lesions due to desferrioxamine","volume":"155","author":"De Sanctis","year":"1996","journal-title":"Eur J Pediatr"},{"issue":"4","key":"10.1016\/j.hoc.2004.06.019_bib51","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0022-3476(88)80375-5","article-title":"Deferoxamine-induced growth retardation in patients with thalassemia major","volume":"113","author":"De Virgiliis","year":"1988","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.hoc.2004.06.019_bib52","first-page":"565","article-title":"Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions","volume":"144","author":"Freedman","year":"1990","journal-title":"Am J Dis Child"},{"issue":"3 Pt 1","key":"10.1016\/j.hoc.2004.06.019_bib53","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0022-3476(98)70022-8","article-title":"Plasma zinc status, growth, and maturation in children with sickle cell disease","volume":"132","author":"Leonard","year":"1998","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib54","first-page":"48","article-title":"Iron chelation by deferoxamine in sickle cell patients with severe tranfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship","volume":"122","author":"Silliman","year":"1993","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.hoc.2004.06.019_bib55","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(00)02357-6","article-title":"Survival in beta thalassaemia-major in the U. K.: data from the UK Thalassaemia Register","volume":"355","author":"Modell","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2004.06.019_bib56","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1749-6632.1998.tb10479.x","article-title":"Survival and disease complications in thalassemia major","volume":"850","author":"Borgna-Pignatti","year":"1998","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib57","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000203853","article-title":"Results of long-term iron chelating therapy","volume":"95","author":"Gabutti","year":"1996","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib58","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0022-3476(89)80353-1","article-title":"Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy","volume":"115","author":"Cohen","year":"1989","journal-title":"J Pediatr"},{"issue":"9","key":"10.1016\/j.hoc.2004.06.019_bib59","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood.V95.9.2776.009k26_2776_2779","article-title":"Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload","volume":"95","author":"Franchini","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2004.06.019_bib60","first-page":"121a","article-title":"A phase 1b study of the safety, pharmacokinetics, acute tolerability, and efficacy of ascending single doses of 40SD02 (CHF5140, GS 460) in iron-loaded patients","volume":"102","author":"Harmatz","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2004.06.019_bib61","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1046\/j.1365-2141.1996.d01-1743.x","article-title":"A novel delivery system for continuous deferrioxamine infusion in transfusional iron overload","volume":"93","author":"Araujo","year":"1996","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib62","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/blood.V91.1.295","article-title":"Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients","volume":"91","author":"Hoffbrand","year":"1998","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib63","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.1995.tb05274.x","article-title":"Results of long-term deferiprone (L1) therapy: a report by the International Study Group on oral iron chelators","volume":"91","author":"Al-Refaie","year":"1995","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2004.06.019_bib64","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood.V83.8.2329.2329","article-title":"Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4 -one (L1) in iron-loaded patients with sickle cell disease","volume":"83","author":"Collins","year":"1994","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2004.06.019_bib65","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2141.1995.tb03318.x","article-title":"Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload","volume":"89","author":"Al-Refaie","year":"1995","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2004.06.019_bib66","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/clpt.1991.139","article-title":"Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4\u20131 in patients with thalassemia","volume":"50","author":"Matsui","year":"1991","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.hoc.2004.06.019_bib67","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/blood.V80.3.593.593","article-title":"Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major","volume":"80","author":"Al-Refaie","year":"1992","journal-title":"Blood"},{"issue":"6612","key":"10.1016\/j.hoc.2004.06.019_bib68","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1136\/bmj.295.6612.1509","article-title":"Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4\u20131","volume":"295","author":"Kontoghiorghes","year":"1987","journal-title":"BMJ"},{"issue":"8726","key":"10.1016\/j.hoc.2004.06.019_bib69","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/0140-6736(90)92962-H","article-title":"Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients","volume":"336","author":"Olivieri","year":"1990","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hoc.2004.06.019_bib70","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2141.1992.tb06445.x","article-title":"Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial","volume":"82","author":"Agarwal","year":"1992","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2004.06.019_bib71","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1046\/j.1365-2141.1998.01002.x","article-title":"Combined therapy with deferiprone and desferrioxamine","volume":"103","author":"Wonke","year":"1998","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2004.06.019_bib72","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199808133390701","article-title":"Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major","volume":"339","author":"Olivieri","year":"1998","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.hoc.2004.06.019_bib73","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJM199504063321404","article-title":"Iron-chelation therapy with oral deferiprone in patients with thalassemia major","volume":"332","author":"Olivieri","year":"1995","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2004.06.019_bib74","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","article-title":"Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib75","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-2141.2002.03554.x","article-title":"The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients","volume":"118","author":"Ceci","year":"2002","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2004.06.019_bib76","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/bcmd.2002.0510","article-title":"Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial","volume":"28","author":"Maggio","year":"2002","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"10.1016\/j.hoc.2004.06.019_bib77","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2141.2000.01866.x","article-title":"Safety profile of the oral iron chelator deferiprone: a multicentre study","volume":"108","author":"Cohen","year":"2000","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2004.06.019_bib78","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1046\/j.1365-2141.2003.04297.x","article-title":"Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry","volume":"121","author":"Fischer","year":"2003","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2004.06.019_bib79","first-page":"496","article-title":"Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia","volume":"83","author":"Mazza","year":"1998","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib80","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1034\/j.1600-0609.2001.067001030.x","article-title":"Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients","volume":"67","author":"Taher","year":"2001","journal-title":"Eur J Haematol"},{"issue":"933d","key":"10.1016\/j.hoc.2004.06.019_bib81","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(02)09740-4","article-title":"Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia","volume":"360","author":"Anderson","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.hoc.2004.06.019_bib82","first-page":"489","article-title":"Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis","volume":"88","author":"Piga","year":"2003","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.hoc.2004.06.019_bib83","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1600-0609.1994.tb01323.x","article-title":"Deferiprone-associated myelotoxicity","volume":"53","author":"Al-Refaie","year":"1994","journal-title":"Eur J Haematol"},{"issue":"8736","key":"10.1016\/j.hoc.2004.06.019_bib84","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/0140-6736(91)90906-6","article-title":"Fatal systemic lupus erythematosus in patient taking oral iron chelator L1","volume":"337","author":"Mehta","year":"1991","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hoc.2004.06.019_bib85","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1365-2141.1997.d01-2014.x","article-title":"Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone)","volume":"96","author":"Castriota-Scanderbeg","year":"1997","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2004.06.019_bib86","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.1998.00725.x","article-title":"Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients","volume":"101","author":"Tondury","year":"1998","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2004.06.019_bib87","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood-2002-01-0306","article-title":"Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia","volume":"100","author":"Wanless","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2004.06.019_bib88","first-page":"493","article-title":"Combined oral and parenteral iron chelation in beta thalassaemia major","volume":"55","author":"Balveer","year":"2000","journal-title":"Med J Malaysia"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib89","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.04240.x","article-title":"Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients","volume":"121","author":"Mourad","year":"2003","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2004.06.019_bib90","first-page":"120a","article-title":"Safety and efficacy of combining deferiprone and deferoxamine in iron chelation therapy in patients with thalassemia","volume":"100","author":"Kattamis","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2004.06.019_bib91","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1182\/blood.V97.3.792","article-title":"Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy","volume":"97","author":"Breuer","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2004.06.019_bib92","first-page":"565","article-title":"Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia","volume":"43","author":"Galanello","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"9369","key":"10.1016\/j.hoc.2004.06.019_bib93","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(03)13309-0","article-title":"Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"361","author":"Nisbet-Brown","year":"2003","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.hoc.2004.06.019_bib94","first-page":"121a","article-title":"Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy","volume":"102","author":"Piga","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2004.06.019_bib95","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2174\/0929867033457610","article-title":"Development of tridentate iron chelators: from desferrithiocin to ICL670","volume":"10","author":"Nick","year":"2003","journal-title":"Curr Medic Chem"},{"issue":"7","key":"10.1016\/j.hoc.2004.06.019_bib96","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1182\/blood.V79.7.1657.1657","article-title":"A modified transfusion program for prevention of stroke in sickle cell disease","volume":"79","author":"Cohen","year":"1992","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2004.06.019_bib97","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood.V83.4.1136.1136","article-title":"Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease","volume":"83","author":"Kim","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib98","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V55.1.55.55","article-title":"New approaches to the transfusion management of thalassemia","volume":"55","author":"Propper","year":"1980","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2004.06.019_bib99","series-title":"The clinical approach to thalassaemia","author":"Modell","year":"1984"},{"issue":"4","key":"10.1016\/j.hoc.2004.06.019_bib100","first-page":"262","article-title":"The management of patients with Cooley's anemia: transfusion and splenectomy","volume":"32","author":"Piomelli","year":"1995","journal-title":"Sem Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2004.06.019_bib101","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/blood.V57.3.599.599","article-title":"Selective isolation of young erytrhocytes for transfusion support of thalassemia major patients","volume":"57","author":"Corash","year":"1981","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2004.06.019_bib102","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.V59.4.865.865","article-title":"A simple technique for preparation of young red cells for transfusion from ordinary blood units","volume":"59","author":"Graziano","year":"1982","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2004.06.019_bib103","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1073\/pnas.75.7.3474","article-title":"Separation of younger red cells with improved survival in vivo: an approach to chronic transfusion therapy","volume":"75","author":"Piomelli","year":"1978","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.hoc.2004.06.019_bib104","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1537-2995.1994.34694295068.x","article-title":"Comparison of a transfusion preparation of newly formed red cells and standard washed red cell transfusions in patients with homozygous beta-thalassemia","volume":"34","author":"Collins","year":"1994","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.hoc.2004.06.019_bib105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2141.1985.tb07396.x","article-title":"A prospective trial of young red cells in 48 patients with transfusion-dependent thalassaemia","volume":"60","author":"Marcus","year":"1985","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2004.06.019_bib106","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0022-3476(84)80482-5","article-title":"Clinical trial of young red cell transfusions","volume":"104","author":"Cohen","year":"1984","journal-title":"J Pediatr"},{"issue":"11","key":"10.1016\/j.hoc.2004.06.019_bib107","first-page":"121a","article-title":"Erythrocytapheresis to reduce iron loading in thalassemia","volume":"102","author":"Friedman","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2004.06.019_bib108","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2257.1986.tb00097.x","article-title":"A study on the value of red cell exchange transfusion in transfusion dependent anaemias","volume":"8","author":"Berdoukas","year":"1986","journal-title":"Clin Lab Haematol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858804000826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858804000826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:37:08Z","timestamp":1760182628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858804000826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":108,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S0889858804000826"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2004.06.019","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2004.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}